Search Results - "Marttila, Anu"

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS by Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Pečeliūnas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Axelsson, Per, Svensson, Ronald, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Hoyseter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth

Get full text

The Case | Refractory anemia in a patient undergoing dialysis by Kaartinen, Kati, Schenk, Päivi, Räisänen-Sokolowski, Anne, Dunkel, Johannes, Marttila, Anu, Huuskonen, Mika, Varmavuo, Ville

Get more information

Multiple myeloma treatment patterns, outcomes, and costs during 2009-2016, identified with multiple data sources from a hospital district in Finland by Salonen, Jonna, Torvinen, Saku, Vihervaara, Ville, Miettinen, Tatu, Jokelainen, Jari, Bauer, Melissa, Marttila, Anu, Tamminen, Klaus

Get full text

Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients by Silvennoinen, Raija Helena, Nahi, Hareth, Anttila, Pekka, Koskenvesa, Perttu, Lievonen, Juha, Marttila, Anu, Varmavuo, Ville, Sikiö, Anu, Nurmi, Marita, Säily, Marjaana, Partanen, Anu, Sankelo, Marja, Luoma, Sini, Mäntymaa, Pentti, Ilveskero, Sorella, Rode Eshoj, Henrik, Nielsen, Lene Kongsgaard, Jantunen, Esa, Heckman, Caroline A

“…Introduction: Due to its heterogenous nature including evolving mutations, multiple myeloma (MM) is still an incurable disease. Several novel agents have been…”
Get full text

P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients by Silvennoinen, Raija, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Partanen, Anu, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Nahi, Hareth

Get full text

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients by Silvennoinen, Raija Helena, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukaas, Einar, Sankelo, Marja, Partanen, Anu, Szatkowski, Damian L., Hansson, Markus, Marttila, Anu, Ahlberg, Lucia, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija Helena, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Hoysaeter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth

“…Introduction Autologous stem cell transplantation (ASCT) combined with novel agents is considered as the standard treatment for eligible patients < 70(-75)…”
Get full text

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group by Partanen, Anu, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Säily, Marjaana, Uttervall, Katarina, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Fenstad, Mona Hoysaeter, Ilveskero, Sorella, Pelliniemi, Tarja-Terttu, Nahi, Hareth, Silvennoinen, Raija

“…Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study…”
Get full text